Okay, so I need to figure out the answer to this question about permanent interstitial implant brachytherapy. Let me start by recalling what brachytherapy is. Brachytherapy is a type of radiation therapy where the radiation source is placed inside or next to the area requiring treatment. It's used for various cancers, like prostate, cervical, and breast cancers.

The question is asking which option is used for permanent interstitial implant brachytherapy. Permanent implants are those where the radioactive seeds or sources are left in the body permanently. These seeds typically have a half-life that allows them to deliver the necessary radiation dose over time and then become non-radioactive.

Now, I need to remember the common isotopes used in brachytherapy. For permanent implants, common isotopes include Iodine-125 (I-125) and Palladium-103 (Pd-103). These have low energy and short half-lives, making them suitable for permanent placement. For example, I-125 has a half-life of about 59 days, and Pd-103 is around 17 days. They are often used in prostate brachytherapy.

Temporary brachytherapy might use isotopes like Cesium-137 or Iridium-192, which have higher energy and are removed after the treatment is done. So if the question is about permanent implants, the correct answer should be either I-125 or Pd-103.

Looking at the options, if any of them list I-125 or Pd-103, that would be the right choice. The other options might include isotopes used for temporary implants or external beam radiation. For instance, Cobalt-60 is used in external beam therapy, not implants. Strontium-90 is used for skin treatments, maybe in superficial lesions.

So the key here is distinguishing between permanent and temporary brachytherapy isotopes. The permanent ones are the ones that decay over time and remain in the body. Therefore, the correct answer is likely Iodine-125.

**Core Concept**
Permanent interstitial brachytherapy involves implanting radioactive seeds (e.g., iodine-125 or palladium-103) directly into a tumor. These isotopes emit low-energy radiation over weeks to months, targeting localized cancers like prostate cancer while minimizing systemic exposure.

**Why the Correct Answer is Right**
Iodine-125 (I-125) is the gold standard for permanent interstitial brachytherapy. It emits low-energy gamma rays (27–31 keV) and has a half-life of 59.4 days, allowing sustained tumor irradiation while minimizing damage to surrounding tissues. Seeds are implanted via needles and remain permanently, becoming inert over time. This modality is FDA-approved for prostate cancer and select gynecologic malignancies.

**Why Each Wrong Option is Incorrect**
**Option A:** Cesium-137 is used in temporary brachytherapy (e.g., high-dose-rate treatments) due to its higher energy and shorter half-life (30.17 years), requiring removal after treatment.
**Option B:** Iridium-192 is used in high-d

✓ Correct Answer: B. Cesium 133